Business Insider

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and ...

There are currently no approved vaccines or treatments for norovirus infection Cocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by ...
Hosted on MSN

Cocrystal Pharma’s norovirus antiviral study receives FDA clearance

Cocrystal Pharma has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to conduct a Phase Ib challenge trial of pan-viral 3CL protease inhibitor CDI-988, ...
Business Insider

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company’s previous Phase 2b challenge study - SOUTH SAN ...